Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Combinations in Solid Tumors
NCT02715531Phase 1Completed
- Sponsor
- Roche
- Start
- Apr 2016
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, randomised, open-label trial of atezolizumab in hepatocellular carcinoma (HCC), gastric cancer (GC), pancreatic cancer (PC) and 1 more (5 arms), sponsored by Roche. Primary endpoints: Number of Participants With At Least One Adverse Event up to 55 months, Percentage of Participants with Objective Response as Determined By The Independent Review Facility (IRF) According To RECIST v1.1 up to 55 months and 1 more. Started Apr 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
hepatocellular carcinoma (HCC)gastric cancer (GC)pancreatic cancer (PC)esophageal cancer
Beyond the preview
Go deeper on NCT02715531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02715531.